Literature DB >> 6222110

Interleukin 2-dependent natural killer (NK) cell lines from patients with primary T cell immunodeficiencies.

N Flomenberg, K Welte, R Mertelsmann, R O'Reilly, B Dupont.   

Abstract

Bulk cultured cell lines with natural killer (NK) activity were derived by in vitro culture with interleukin 2-containing conditioned medium (IL 2-CM) of peripheral blood mononuclear leukocytes (PBL) from patients with primary T cell deficiencies. Lines were developed from three patients with severe combined immunodeficiency (SCID) and one patient with Nezelof's syndrome and contained several populations of cells with distinct phenotypes. All lines contained a cell population expressing the Leu-5 (50K) (sheep red blood cell receptor), 3A1 (40K), and OKT10 antigens, but lacking the pan T cell antigens Leu-1 (67K) and Leu-4 (19K) as well as the markers of T cell subsets Leu-2a (32K) and Leu-3a (56K). These cells failed to express the Leu-7 antigen and only weakly expressed OKM1. In addition, one line contained a population of Leu-5+, 3A1+, OKT10+, Leu-2a+, Leu 1-, and Leu 4- cells. Three of the lines also contained populations with classic T cell (Leu-1 and-Leu 4+) phenotypes. The lines were enriched in NK activity compared with the PBL from which they were derived. Their growth was strictly dependent on IL 2-CM. Highly purified IL 2, lacking any other detectable protein contaminants or lymphokine activities, was capable of supporting the growth of the Leu-5+, 3A1+ "null" cell populations from these lines without alteration in their functional activity or phenotype. Thus, studies of in vitro expanded cell lines from patients with severe disorders of T cell function and thymic involution indicate that this "null" cell population does not require thymic maturation to develop its effector function. This "null" cell population can be maintained in vitro in the presence of IL 2. This finding is analogous to the data obtained from study of NK cells in athymic (nude) mice.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6222110

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Photoaffinity labeling of ATP and NAD+ binding sites on recombinant human interleukin 2.

Authors:  S Campbell; H Kim; M Doukas; B Haley
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

2.  [Growth factors. A new dimension in understanding oncogenesis].

Authors:  V Heinemann; U Jehn
Journal:  Klin Wochenschr       Date:  1985-08-16

3.  The interleukin 2 gene is expressed in the syncytiotrophoblast of the human placenta.

Authors:  K D Boehm; M F Kelley; J Ilan; J Ilan
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

4.  Astrocytoma linked to familial ataxia-telangiectasia.

Authors:  K Miyagi; J Mukawa; N Kinjo; K Horikawa; S Mekaru; S Nakasone; H Koga; Y Higa; M Naito
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

Review 5.  Inflammatory mediators in chronic inflammatory bowel diseases.

Authors:  V Gross; T Andus; H G Leser; M Roth; J Schölmerich
Journal:  Klin Wochenschr       Date:  1991-12-15

6.  Lymphocytes from patients with hairy cell leukaemia enable the distinction of two separate subpopulations of activated lymphocyte killer cells generated in mixed lymphocyte culture.

Authors:  J A Werkmeister; A W Boyd; T Triglia; G F Burns
Journal:  Clin Exp Immunol       Date:  1985-07       Impact factor: 4.330

7.  Locoregional therapy with polyethylene-glycol-modified interleukin-2 of an intradermally growing hepatocellular carcinoma in the guinea pig induces T-cell-mediated antitumor activity.

Authors:  L T Balemans; V Mattijssen; P A Steerenberg; B E Van Driel; P H De Mulder; W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1993-07       Impact factor: 6.968

8.  Interleukin 2 regulates the expression of Tac antigen on peripheral blood T lymphocytes.

Authors:  K Welte; M Andreeff; E Platzer; K Holloway; B Y Rubin; M A Moore; R Mertelsmann
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.